Event Date/Time: Sep 27, 2005
End Date/Time: Sep 28, 2005
The rising costs of drug development are putting pressure on pharmaceutical companies to reduce clinical attrition and maximize decision-making at the pre-clinical stage. One of the keys to reducing the cost and time of drug development is early and accurate safety evaluation of candidate drugs. The growing understanding of the toxicity mechanisms is creating an opportunity to develop toxicity biomarkers at the pre-clinical, clinical, and post-market stages. The Toxicity Biomarkers meeting will outline specific strategies and case studies necessary to realize and derive value from this information.